These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31419452)

  • 1. Speech in prodromal and symptomatic Huntington's disease as a model of measuring onset and progression in dominantly inherited neurodegenerative diseases.
    Chan JCS; Stout JC; Vogel AP
    Neurosci Biobehav Rev; 2019 Dec; 107():450-460. PubMed ID: 31419452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Listener Detection of Objectively Validated Acoustic Features of Speech in Huntington's Disease.
    Chan JCS; Stout JC; Shirbin CA; Vogel AP
    J Huntingtons Dis; 2022; 11(1):71-79. PubMed ID: 34974436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Speech acoustic markers of early stage and prodromal Huntington's disease: a marker of disease onset?
    Vogel AP; Shirbin C; Churchyard AJ; Stout JC
    Neuropsychologia; 2012 Dec; 50(14):3273-8. PubMed ID: 22982606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Speech biomarkers in Huntington's disease: A cross-sectional study in pre-symptomatic, prodromal and early manifest stages.
    Kouba T; Frank W; Tykalova T; Mühlbäck A; Klempíř J; Lindenberg KS; Landwehrmeyer GB; Rusz J
    Eur J Neurol; 2023 May; 30(5):1262-1271. PubMed ID: 36732902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Language disintegration in spontaneous speech in Huntington's disease: a more fine-grained analysis.
    Tovar A; Garí Soler A; Ruiz-Idiago J; Mareca Viladrich C; Pomarol-Clotet E; Rosselló J; Hinzen W
    J Commun Disord; 2020; 83():105970. PubMed ID: 32062158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognition in Huntington's disease in manifest, premanifest and converting gene carriers over ten years.
    Hart EP; Dumas EM; Giltay EJ; Middelkoop HA; Roos RA
    J Huntingtons Dis; 2013; 2(2):137-47. PubMed ID: 25063511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic linguistic profile of spontaneous narrative speech in pre-symptomatic and early stage Huntington's disease.
    Hinzen W; Rosselló J; Morey C; Camara E; Garcia-Gorro C; Salvador R; de Diego-Balaguer R
    Cortex; 2018 Mar; 100():71-83. PubMed ID: 28859906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
    Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic criteria for Huntington's disease based on natural history.
    Reilmann R; Leavitt BR; Ross CA
    Mov Disord; 2014 Sep; 29(11):1335-41. PubMed ID: 25164527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intact sensory-motor network structure and function in far from onset premanifest Huntington's disease.
    Gorges M; Müller HP; Mayer IM; Grupe GS; Kammer T; Grön G; Kassubek J; Landwehrmeyer GB; Wolf RC; Orth M
    Sci Rep; 2017 Mar; 7():43841. PubMed ID: 28266655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired postural stability as a marker of premanifest Huntington's disease.
    Salomonczyk D; Panzera R; Pirogovosky E; Goldstein J; Corey-Bloom J; Simmons R; Gilbert PE
    Mov Disord; 2010 Oct; 25(14):2428-33. PubMed ID: 20818666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver function in Huntington's disease assessed by blood biochemical analyses in a clinical setting.
    Nielsen SM; Vinther-Jensen T; Nielsen JE; Nørremølle A; Hasholt L; Hjermind LE; Josefsen K
    J Neurol Sci; 2016 Mar; 362():326-32. PubMed ID: 26944172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compromised Dopaminergic Encoding of Reward Accompanying Suppressed Willingness to Overcome High Effort Costs Is a Prominent Prodromal Characteristic of the Q175 Mouse Model of Huntington's Disease.
    Covey DP; Dantrassy HM; Zlebnik NE; Gildish I; Cheer JF
    J Neurosci; 2016 May; 36(18):4993-5002. PubMed ID: 27147652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease.
    Martinez-Horta S; Perez-Perez J; van Duijn E; Fernandez-Bobadilla R; Carceller M; Pagonabarraga J; Pascual-Sedano B; Campolongo A; Ruiz-Idiago J; Sampedro F; Landwehrmeyer GB; ; Kulisevsky J
    Parkinsonism Relat Disord; 2016 Apr; 25():58-64. PubMed ID: 26898966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual Working Memory Impairment in Premanifest Gene-Carriers and Early Huntington's Disease.
    Dumas EM; Say MJ; Jones R; Labuschagne I; O'Regan AM; Hart EP; van den Bogaard SJ; Queller S; Justo D; Coleman A; Dar Santos RC; Dürr A; Leavitt BR; Tabrizi SJ; Roos RA; Stout JC
    J Huntingtons Dis; 2012; 1(1):97-106. PubMed ID: 25063192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Striatal hypometabolism in premanifest and manifest Huntington's disease patients.
    López-Mora DA; Camacho V; Pérez-Pérez J; Martínez-Horta S; Fernández A; Sampedro F; Montes A; Lozano-Martínez GA; Gómez-Anson B; Kulisevsky J; Carrió I
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2183-2189. PubMed ID: 27349245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in cognitive control in pre-manifest Huntington's disease examined using pre-saccadic EEG potentials - a longitudinal study.
    Ness V; Bestgen AK; Saft C; Beste C
    J Huntingtons Dis; 2014; 3(1):33-43. PubMed ID: 25062763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cortical thickness, stance control, and arithmetic skill: An exploratory study in premanifest Huntington disease.
    Nanetti L; Contarino VE; Castaldo A; Sarro L; Bachoud-Levi AC; Giavazzi M; Frittoli S; Ciammola A; Rizzo E; Gellera C; Bruzzone MG; Taroni F; Grisoli M; Mariotti C
    Parkinsonism Relat Disord; 2018 Jun; 51():17-23. PubMed ID: 29496355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Grasping premanifest Huntington's disease - shaping new endpoints for new trials.
    Reilmann R; Bohlen S; Klopstock T; Bender A; Weindl A; Saemann P; Auer DP; Ringelstein EB; Lange HW
    Mov Disord; 2010 Dec; 25(16):2858-62. PubMed ID: 20818671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
    Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.